The Definitive Guide to European Nootropics 2027
Regulation, dosing, transparency — a complete framework for cognitive supplements in the European Union.
The European nootropic market in 2027 has entered a new phase. Where 2020-2024 was dominated by US-style opaque formulations dressed in wellness aesthetics, the European operator now demands what the American market has resisted for a decade: every milligram declared on the label, every claim traceable to peer-reviewed research, every ingredient sourced under EU GMP.
This guide is written for the discerning European buyer. It covers what regulation actually requires, how to read a nootropic label like a formulator would, which compounds have real evidence at real doses, and how the European framework differs fundamentally from the US supplement industry.
Written by Andreas C., founder of LIMINATE (Brussels, 2026). This document reflects four years of formulation research. It is not medical advice.
The regulatory framework you need to understand.
EU Regulation 1924/2006: the health claims regulation
Every nootropic sold in the European Union operates under Regulation 1924/2006 on nutrition and health claims. This is why European supplement labels look so different from American ones. A US brand can claim "supports focus, mental clarity, and executive function" on the front of the box. A European brand cannot — unless every one of those phrases has been submitted to and authorized by the European Food Safety Authority (EFSA).
Most nootropic-adjacent claims are not authorized under EU Regulation 432/2012. This is not a bureaucratic failure — it is the correct response to decades of unverified marketing claims.
The 75 mg caffeine threshold
A regulatory detail rarely discussed: Regulation 432/2012 permits specific cognitive claims for caffeine ("helps to increase alertness") only at doses at or above 75 mg per serving. This is why so many European nootropics dose caffeine at exactly 75-100 mg.
An alternative approach is to deliberately calibrate below the 75 mg threshold. This means giving up the authorized claim but gaining access to what the paired-compound literature (Owen et al., 2008) demonstrates: caffeine at sub-100 mg doses, paired with L-Theanine at a 1:3-1:4 ratio, produces a distinct cognitive state — clear activation without the jitter, focus without the crash.
At LIMINATE we chose 70 mg deliberately, paired with 255 mg of L-Theanine at a 1:3.6 ratio.
The FAMHP notification (Belgium)
In Belgium, every food supplement must be notified to the AFMPS/FAMHP before commercialization. Similar bodies exist across the EU: DGCCRF in France, BVL in Germany, NVWA in the Netherlands.
EU GMP versus food-grade manufacturing
"Manufactured in Europe" and "Manufactured under EU GMP" are not the same thing. EU GMP is a pharmaceutical-grade standard. It costs 3-5x more than food-grade manufacturing.
Five questions to ask of any nootropic.
What are all the active compounds and their individual doses?
If the label says "Focus Blend: 850 mg" without individual doses, you are looking at a proprietary blend — the American formulation trick that hides the fact that most ingredients are dosed far below their evidence-based threshold.
What is the third-party testing regime?
Every serious brand should test every batch through an independent laboratory. Eurofins Antwerp is one of the most reputable European testing labs for supplements.
Who is legally responsible?
Is there a real company with a real address, a VAT number, and a named founder? If not, the brand is either not properly established or hiding.
What is the evidence behind each active compound?
The caffeine-L-theanine pairing at 1:3 to 1:4 ratio is backed by Owen et al., 2008. Acetyl-L-Tyrosine by Deijen et al., 1999. Rhodiola rosea by Darbinyan et al., 2000.
What does the brand refuse?
LIMINATE publishes this as the Charter of Refusals — ten specific commitments, signed, dated, non-modifiable.
The compounds that have real evidence.
Cognitive foundations
Documented effect on cognitive performance under stress. LUCID uses 650 mg.
Supports phospholipid synthesis. Effect on attention (McGlade 2012). LUCID uses 350 mg.
Complements citicoline via the Kennedy pathway. LUCID uses 100 mg.
Adaptogenic support
Stress fatigue and mental endurance (Darbinyan 2000). LUCID uses 300 mg.
Alpha-wave induction and caffeine synergy (Owen 2008). LUCID uses 255 mg.
Mood stability (Lopresti 2014, Marx 2019). LUCID uses 28 mg of Safr'inside.
State calibration
Effective at 40–100 mg paired with L-Theanine at 1:3–1:4 ratio. LUCID uses 70 mg + 255 mg L-Theanine.
Circulation and adaptogenic support. LUCID uses 50 mg.
Bioavailability
Enhances absorption (Shoba 1998). LUCID uses 5 mg.
How LIMINATE compares to the major categories.
LUCID vs Athletic Greens (AG1)
AG1: 75-ingredient greens powder with proprietary matrix, no caffeine. LUCID: focused cognitive formula with 10 declared actives, no proprietary blends, calibrated caffeine (70 mg) + L-Theanine.
LUCID vs Qualia Mind
Qualia Mind: 28 ingredients with proprietary blends, 7 capsules per daily serving. LUCID: 10 declared actives, no proprietary blends, 3 capsules per serving.
LUCID vs Onnit Alpha Brain
Alpha Brain uses three proprietary blends. LUCID has every milligram declared on the front of the box.
LUCID vs Bryan Johnson Blueprint
Blueprint is a 60+ pill longevity protocol. LUCID is a single morning ritual (3 capsules).
LUCID vs Mind Lab Pro
Mind Lab Pro is caffeine-free. LUCID includes 70 mg of caffeine paired with L-Theanine at 1:3.6 ratio.
The path forward for European cognitive supplements.
The European market is entering a phase where transparency, regulation compliance, and evidence-grounded formulation are becoming table stakes.
- Complete milligram transparency — every active named, every dose disclosed.
- Peer-reviewed traceability — every claim backed by specific studies.
- EU GMP manufacturing — pharmaceutical-grade, not food-grade.
- Third-party testing — every batch verified independently.
- Named responsibility — real founders, real addresses, real accountability.
- Refusal-first marketing — no influencer contracts, no manufactured urgency.
Compiled and signed in Brussels. Held in the Reading Room. Amendable, in writing, in the Decision Register.
Further reading
within the House.
Andreas C. is the founder of LIMINATE (Brussels, 2026). This document reflects four years of formulation research. It is not medical advice. LUCID is a food supplement, not a medicine.
